Stay Updated with the Latest CRISPR Therapeutics AG CRSP News in Real Time
Find CRSP news now at Meyka AI. Stay informed with the latest CRISPR Therapeutics AG stocks updates, including price news, market analysis, and expert insights.
Abivax Shares Jump 3.91% After $920 Million Stock Offering Grows Beyond Expectations
Abivax shares climbed 3.91% on Nasdaq on July 2, 2026, after the French biotech confirmed its $920 million American Depositary Share offering. Underwriters exercised their full option, pushing gross proceeds well past the original $600 million target. The ADS offering priced at $125.00 apiece on July 1. Abivax (Nasdaq: ABVX, Euronext Paris: ABVX) said the…
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal, Offering Nearly 50% Premium
AbbVie made a major move in the biotech sector on June 22, 2026, announcing a $10.9 billion deal to acquire Apogee Therapeutics. The transaction offers Apogee shareholders nearly a 50% premium and gives AbbVie access to a promising pipeline of immunology treatments. As competition grows in the market for inflammatory disease therapies, this acquisition could…
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns
French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…
IMMX Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on IMMX, raises price target to $20 from $15 on May 22, 2026.
XOMA Downgraded to Hold from Buy at Benchmark May 22
Benchmark downgraded XOMA to Hold from Buy on May 22, 2026. Stock trades at $41.65 with mixed analyst sentiment.
ROIV Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Roivant Sciences (ROIV) at Overweight rating, citing mosliciguat Phase 2 catalysts and 2026 pipeline strength.
UTHR Maintained at Buy by Cowen & Co., May 2026
Cowen & Co. maintains Buy rating on United Therapeutics (UTHR) as a top biotech idea with strong fundamentals.
UTHR Stock: Officer Paul Mahon Sells 8,300 Shares May 22, 2026
United Therapeutics EVP Paul Mahon sold 8,300 stock options for $1.21M on May 21, 2026. Latest insider trading activity.
MindMaze Therapeutics Holding Surges 13.8% on Biotech Recovery
MMTX.SW stock jumps 13.8% to CHF0.4895 on SIX. MindMaze Therapeutics gains momentum in digital therapeutics sector.